Abstract • 189

41 children(age 11 mo-15 years) with marphocytochemically confirmed AML(FAB M0-M5) were identically treated according to protocol mBFM-87. Most of patients received treatment before 1993, so median folloup was 52,51 mo. Bone marrow leukemic cells from all patients were immunophenotyped for myeloid(CD11b,CD13,CD14,CD15,CD33),B-lineage(CD19,CD22,CD37),T-lineage (CD1a, CD2, CD3, CD4, CD5, CD7), erythroid (erythroblastic antigen, glycophorine A) and other antigens (CD10, CD38, CD34, HLA-DR). Prognosis was estimated according to standard criteria: disease-free survival(DFS), event-free survival(EFC) and overall survival(OS). Myeloid antigen expression did not influences on DFS, EFS and OS. Expression of T-cell antigens was associated with longer DFS(p=0,02), as well as longer OS.

B-cell antigen expression negatively influences the prognosis: shorter DFS(p=0,04) The most important immunological prognostic factor was the expression of HLA-DR: HLA-DR-negative group had the most favorite disease outcome-EFS,OS,DFS(p=0,006). The last finding is of course partially associated with HLA-DR -negativity in M3-variant. So, our data confirmed the prognostic importance of some immunological markers in childhood AML treated according to modern intensive chemotherapy programmer.